Competitive HMG-CoA reductase inhibitor (IC50 = 40 - 100 nM in human and rat microsomes). Potent inhibitor of vascular smooth muscle cell proliferation in vitro (IC50 = 70 nM).
(±)-(3R*,5S*,6E)-7-[3-(4-Fluorophenyl)-1-(1-methyethyl)-1H-indol-2-yl]-3,5-dihydroxy-6-heptenoic acid sodium salt
Store at -20°C. Store under desiccating conditions. The product can be stored for up to 12 months.
Soluble in DMSO to 100 mM and in water to 50 mM
Wherever possible, you should prepare and use solutions on the same day. However, if you need to make up stock solutions in advance, we recommend that you store the solution as aliquots in tightly sealed vials at -20°C. Generally, these will be useable for up to one month. Before use, and prior to opening the vial we recommend that you allow your product to equilibrate to room temperature for at least 1 hour.
ab90529 staining cytochrome C in HepG2 cells treated with fluvastatin sodium salt (ab120651), by ICC/IF. Increase of cytochrome C expression correlates with increased concentration of fluvastatin sodium salt, as described in literature. The cells were incubated at 37°C for 48 hours in media containing different concentrations of ab120651 (fluvastatin sodium salt) in DMSO, fixed with 4% formaldehyde for 10 minutes at room temperature and blocked with PBS containing 10% goat serum, 0.3 M glycine, 1% BSA and 0.1% tween for 2h at room temperature. Staining of the treated cells with ab90529 (1 µg/ml) was performed overnight at 4°C in PBS containing 1% BSA and 0.1% tween. A DyLight 488 anti-rabbit polyclonal antibody (ab96899) at 1/250 dilution was used as the secondary antibody. Nuclei were counterstained with DAPI and are shown in blue.
This product has been referenced in:
Yang J et al. The cardioprotective effect of fluvastatin on ischemic injury via down-regulation of toll-like receptor 4. Mol Biol Rep38:3037-44 (2011).
Read more (PubMed: 20127518) »
Turner NA et al. Comparison of the efficacies of five different statins on inhibition of human saphenous vein smooth muscle cell proliferation and invasion. J Cardiovasc Pharmacol50:458-61 (2007).
Read more (PubMed: 18049315) »
Morikawa-Futamatsu K et al. HMG-CoA reductase inhibitor fluvastatin prevents angiotensin II-induced cardiac hypertrophy via Rho kinase and inhibition of cyclin D1. Life Sci79:1380-90 (2006).
Read more (PubMed: 16712874) »